angioplasty in the treatment of acute myocardial infarction with a focus on systematic clinical and angiographic follow-up. Patients were enrolled prospectively between July 1990 and February 1992 at six centers experienced with direct angioplasty, and outcomes were analyzed independently by the coordinating center. In-hospital outcomes from the registry have been reported previously. 9 The purpose of this report is to present the 6-month clinical and angiographic follow-up data from the Primary Angioplasty Registry.
Methods Patient Population
Patient selection criteria have been described in the initial report of the registry.9 Patients were considered for enrollment if they had chest pain lasting more than 20 minutes and less than 12 hours, not relieved with sublingual nitroglycerin, and associated with ST-segment elevation on the ECG in two contiguous leads or "reciprocal" ST depression in leads V, to V3. There were no age restrictions, and patients with prior coronary bypass surgery were eligible. Patients with usual contraindications to thrombolytic therapy610 and patients with cardiogenic shock (blood pressure less than 80 mm Hg despite volume loading) were excluded to provide a comparable population to previous US-based thrombolytic trials.
Treatment Protocol
The treatment protocol has been previously described.9
Informed consent was obtained before enrolling eligible patients into the registry. All patients were given three chewable 
Statistical Methods
Descriptive statistics of the baseline characteristics and clinical outcomes are presented as median, 25th, and 75th percentiles for continuous variables and as percentages for discrete variables. Confidence intervals for clinical outcomes were calculated using standard methods. The baseline characteristics of patients with follow-up angiography are compared with patients without follow-up angiography using x2 for discrete variables and Wilcoxon rank sum testing for continuous variables.
Results

Clinical Events Through 6 Months
The clinical events from angioplasty through 6 months are shown in Table 1 . At the six participating centers, 1449 patients were entered into the acute myocardial infarction log during the 19 months of the study. Of the 271 patients who were enrolled in the Primary Angioplasty Registry, there were 10 in-hospital deaths, and 3 patients were lost to follow-up. This left 258 patients who had clinical follow-up through 6 months. There were 5 late deaths, 4 due to congestive heart failure, and 1 sudden death. There were 8 late nonfatal reinfarctions. All of these involved the original infarct-related artery, and 4 underwent repeat emergency angioplasty. Fifty-six patients (22%) reported chest pain in the 6 months after discharge from the hospital; of these, 25 patients (10%) were readmitted to the hospital for recurrent ischemia. 6 patients who had failed angioplasty, 12 patients with successful angioplasty who had bypass surgery during the initial hospitalization, 10 patients who required repeat angioplasty of the infarct-related artery, and 3 patients who had restenosis documented at catheterization during the hospital stay but did not have repeat angioplasty. Of 203 eligible patients, 154 (76%) had follow-up angiography. The median time to follow-up angiography was 180 days.
Eligible patients with and without follow-up angiography are compared with patients ineligible for follow-up angiography in Table 2 . Eligible patients without follow-up angiography were older, more often female, and had more anterior and second infarctions, more previous bypass surgery, and more cerebral vascular disease. They also more often had the left anterior descending artery or a bypass graft as the culprit artery and had better left ventricular function, although in the 6 months after hospitalization they had a lower incidence of recurrent ischemia and repeat angioplasty.
TIMI flow in the infarct artery at 6-month angiography is shown in Fig 2. The infarct artery was patent in 87% (8% with TIMI 2 flow and 79% with TIMI 3 flow). As demonstrated in Table 3 , no major baseline differences were observed in patients with subsequent reocclusion compared with those without reocclusion except that reocclusion was more common when the infarct-related artery was the right coronary artery. Adverse events were common in patients with reocclusion, although only 35% of these patients experienced a clinically evident reinfarction. Repeat angioplasty was performed in 59% of patients with reocclusion, although almost half of these were in patients without ongoing anginal symptoms. The Primary Angioplasty Registry was established to assess outcomes objectively after direct angioplasty for acute myocardial infarction in experienced centers. The major finding of this 6-month follow-up study was the documentation of very low posthospital and cumulative event rates with direct angioplasty in a population eligible for thrombolytic therapy. Our eligibility criteria were selected to provide a patient population comparable to recent American thrombolytic trials16,17 but were broadened to include some of the features present in the international trials.18'9 We sought to expand the eligibility by allowing no age restriction, enrolling patients up to 12 hours after the onset of chest pain, and including patients with prior revascularization.
Our outcomes compare favorably with the best outcomes reported with thrombolytic trials.'6'7 The posthospital and cumulative mortality rates of 2% and 6% are similar to those reported in the TIMI Phase 2 Trial (2.8% and 7.4% at 1 year)'6 and are lower than those reported from earlier American trials (3.5% and 7.7% at 6 months," 4.8% and 8.2% at 6 months20) and the large European thrombolytic trials (5.4% and 13.5% at 1 year,'9 6.5% and 17.2% at 1 year'8). Similar low latemortality rates have been reported with direct angioplasty2,2' and with thrombolytic strategies that used adjunctive angioplasty. 16 the same low death rates can be achieved with a low-risk population, even without frequent intervention.26 Most thrombolytic trials have shown a higher incidence of reinfarctions in patients treated with thrombolytic therapy than in control patients. Both the GISSI trial and the Netherlands intracoronary streptokinase trial found a significantly higher cumulative incidence of reinfarction in patients treated with streptokinase compared with controls at 1 year (GISSI, 7.4% versus 4.6%; Netherlands trial, 13% versus 5%). Our registry showed posthospital and cumulative incidences of nonfatal myocardial infarction of 3% and 6%, respectively. These rates are similar to reports from individual centers with direct angioplasty221 and thrombolytic strategies that have used frequent adjunctive coronary angioplasty. [22] [23] [24] [25] They are lower than those reported from most thrombolytic trials,1118'27 although the 95% confidence intervals for the point estimate do not rule out overlap between our registry and the thrombolytic trials. The low incidence of reinfarction may relate to reduction in the residual luminal stenosis with coronary angioplasty with a concomitant reduction in reocclusion rates.
One of the biggest differences between the outcomes reported in the Primary Angioplasty Registry and outcomes reported from thrombolytic trials is the low incidence of recurrent ischemia with direct angioplasty. Our follow-up data document a low incidence of late recurrent ischemia, similar to our rate of in-hospital recurrent ischemia.9 The 10% incidence of readmission for chest pain through 6 months compares favorably with the 28% incidence of readmissions through 1 year in the TIMI-2 trial.16 Gibbons and colleagues,5 in a prospective randomized comparison, also found fewer readmissions through 6 months with direct angioplasty compared with thrombolytic therapy. This may be related to reduction in residual luminal stenosis with direct angioplasty and perhaps to the aggressive use of additional revascularization. The cumulative incidences of revascularization pro- the most complete and objective angiographic information available after direct angioplasty for acute myocardial infarction. The differences in baseline characteristics between patients with and without follow-up angiography reflect the fact that patients who died or had coronary bypass surgery were not eligible for follow-up angiography and are consistent with previous experience. 28 The late patency rate of 87% documented in our study is higher than late patency rates reported with thrombolytic therapy.7'29 Conversely, our late reocclusion rate of 13% compares favorably with the 25% to 30% reocclusion rate documented at 3 months in the APRICOT study in patients who had achieved successful reperfusion with intravenous streptokinase.29 These data support the recent findings of Zijlstra and colleagues7 who, in a prospective randomized trial, found lower reocclusion rates at 3 months after direct angioplasty (9%) compared with intravenous streptokinase (32%). In our study, reocclusion tended to occur more often when the right coronary artery was the infarctrelated artery and was associated with clinical evidence of reinfarction in only 35% of patients. Approximately half of the patients who developed reocclusion were asymptomatic and could have had silent reocclusion in the hospital, since patients did not have routine angiography before discharge. The low reocclusion rates seen in our registry and other studies with direct angioplasty are probably due to reduction in the residual coronary stenosis and probably account for the low late incidence of nonfatal myocardial infarction. Despite these encouraging results, reocclusion remains a limitation of direct angioplasty as well as other reperfusion strategies.
Our data show substantial improvement in left ventricular ejection fraction between acute and 6-month follow-up angiography. These results are similar to some previous reports of direct angioplasty1 '2,30,31 
Conclusions
The data from the Primary Angioplasty Registry document very favorable clinical outcomes after direct angioplasty for acute myocardial infarction that persist through 6-month follow-up. The 
